Лекарственное лечение метастазов тройного негативного рака молочной железы О. В. Смирнова , 2, В. И. Борисов 1, Л. З. Вельшер 1 гбуз «Онкологический клинический диспансер №1»
жүктеу/скачать 183,23 Kb. Pdf көрінісі
|
Onkologia 2015 06 074 2
| Cancer Res
. 2007;13(8):2329-2334. doi;10.1158/1078-0432.ccr-06-1109. 23. Cardoso F. Metastatic breast cancer patients: the forgotten heroes! The Breast . 2009;18(5):271-272. doi:10.1016/j.breast.2009.09.001. 24. Palmieri C, Krell J, James CR et al. Rechallenging with anthracy- clines and taxanes in metastatic breast cancer. Nat Rev Clin Oncol. 2010;7(10):561-574. doi:10.1038/nrclinonc.2010.122. 25. Sparano JA, Makhson AN, Semiglazov VF et al. Pegylated li- posomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast can- cer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. J Clin Oncol. 2009;27(27):4522-4529. doi:10.1200/jco.2008.20.5013. 26. Alexopoulos A, Karamouzis MV, Stavrinides H et al. Phase II study of pegylated doxorubicin (Caelyx(R)) and docetaxel as first-line treatment in metastatic breast cancer. Ann Oncol. 2004;15(6):891-895. doi:10.1093/annonc/mdh218. 27. Переводчикова Н.И., Стенина М.Б. Практическое руководство по лекарственной терапии рака молочной железы. М.: Практика; 2014:39-40. 28. Viale G, Rotmensz N, Maisonneuve P et al. Invasive ductal car- cinoma of the breast with the «triple-negative» phenotype: prog- nostic implication of EGFR immunoreactivity. Breast Cancer Res Treat. 2009;116(2):317-328. doi:10.1007/s10549-008-0206-z. 29. Baselga J, Stemmer S, Pego A. Cetuximab + cisplatin in estrogen receptor-negative (triple negative) metastatic breast cancer: results of the randomized phase II BALI-1 trial. Cancer Res. 2010;70(24, Suppl.):PD01-01. doi:10.1158/0008-5472.sabcs10-pd01-01. 30. O`Shaughnessy J, Yoffe M, Osborne C et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast can- cer. Breast Cancer Res Treat. 2007;106(1, Suppl.):S32. 31. Carey LA, Rugo H, Marcom P et al. TBCRC 001: Random- ized phase II study of cetuximab in combination with carbo- platin in stage IV triple-negative breast cancer. J Clin Oncol. 2012;30(21):2615-2623. doi:10.1200/jco.2010.34.5579. 32. Finn RS, Press MF, Dering J et al. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. J Clin Oncol. 2009;27(24):3908-3915. doi:10.1200/jco.2008.18.1925. 33. Koshy N, Quispe D, Shi R et al. Cisplatin-gemcitabine therapy in metastatic breast cancer: improved outcome in triple negative breast cancer patients compared to non-triple negative patients. The Breast . 2010;19(3):246-248. doi:10.1016/j.breast.2010.02.003. 34. Gonzalez-Angulo AM, Timms KM, Liu S et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17(5):1082- 1089. doi:10.1158/1078-0432.ccr-10-2560. 35. Byrski T, Gronwald J, Huzarski T et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancer. Breast Cancer Res Treat . 2008;108(2):289-296. doi:10.1007/s10549-007-9600-1. ОБЗОРЫ ЛИТЕРАТУРЫ ОНКОЛОГИЯ. ЖУРНАЛ им. П.А. ГЕРЦЕНА, 6, 2015 81 36. Bhattacharyya GS, Basu S, Agarwal V et al. 41LBA Single institute phase II study of weekly cisplatinum and metronomic dosing cyclophosphamide and methotrexate in second line metastatic breast cancer triple-negative. Eur J Cancer. 2009;7(3,Suppl.):18-19. doi:10.1016/s1359-6349(09)72076-2. 37. Chia GW. Triple-negative metastatic/recurrent breast cancer. J жүктеу/скачать 183,23 Kb. Достарыңызбен бөлісу:
|